Related Experiment Video

Updated: Jul 8, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Molecular targeted therapies for renal cell carcinoma

Sam D Graham1, Mary Elizabeth Warden, Jeffrey Lou

  • 1Urologic Specialists of Virginia, Richmond, VA 23225, USA.

The Canadian Journal of Urology
|February 7, 2008
PubMed

Insights

New targeted therapies show over 70% response rates in advanced renal cell carcinoma, shifting treatment away from immunotherapy. Managing significant toxicities may further improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Translational Medicine

Background:

  • Renal cell carcinoma (RCC) treatment has historically relied on immunotherapy.
  • Advances in molecularly targeted therapies offer new treatment avenues for cancer.

Purpose of the Study:

  • To evaluate the efficacy and safety of novel targeted therapies in advanced renal cell carcinoma.
  • To assess the impact of these targeted agents on treatment paradigms.

Main Methods:

  • Review of recent clinical trials and studies on targeted molecular therapies for RCC.
  • Analysis of response rates, including complete response, in metastatic RCC patients.

Main Results:

  • Targeted therapies achieved response rates exceeding 70% in advanced renal cell carcinoma.
  • Complete responses were observed in a significant proportion of patients with metastatic disease.
  • These results indicate a paradigm shift from traditional immunotherapy.

Conclusions:

  • Novel molecularly targeted therapies represent a significant advancement in treating renal cell carcinoma.
  • While toxicities are notable, they are manageable and optimizing tolerability may enhance response rates.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.